Cellectar Biosc (NQ: CLRB )
1.310 USD +0.040 (+3.15%) Streaming Delayed Price Updated: 4:00 PM EDT, Jun 17, 2021 Add to My Watchlist
All news about Cellectar Biosc
Cellectar Biosciences Inc(NASDAQ: CLRB)announced updated dataat the American Society of Clinical Oncology (ASCO) ...
Gainers Windtree Therapeutics (NASDAQ:WINT) shares rose 35.85% to $2.69 during Friday's regular session. Trading ...
Cellectar Presents Data in Waldenstrom’s Macroglobulinemia in Poster at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
June 04, 2021
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning! Let's get ready for another busy day of trading with a look at the biggest pre-market stock movers for Wednesday. The post...
Gainers Dicerna Pharmaceuticals (NASDAQ:DRNA) stock moved upwards by 4.0% to $31.94 during Tuesday's after-market session. This ...
The Week Ahead In Biotech: ASCO Presentations Front And Center, FDA Decisions Due For Scynexis, Liminal And Alkermes
May 31, 2021
After having declined through the first half of the week, biotech stocks staged a recovery to close higher in the trading week ended May ...
Gainers Cellect Biotechnology (NASDAQ:APOP) shares increased by 7.77% to $3.19 during Thursday's after-market session. Today's ...
Cellectar Announces Poster Presentation of CLR 131 Data in Waldenstrom’s Macroglobulinemia at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
May 20, 2021
Management to host a KOL call with Dr. Sikandar Ailawadhi, M.D., lead investigator on June 4 at 10:00 am
Gainers Lixte Biotech Holdings (NASDAQ:LIXT) shares moved upwards by 16.45% to $3.75 during Tuesday's after-market session. Today's ...
Cellectar to Participate at the Oppenheimer Rare & Orphan Disease Summit on May 21, 2021
May 14, 2021
Gainers Celyad Oncology (NASDAQ:CYAD) stock moved upwards by 12.8% to $5.99 during Wednesday's after-market session. Today's trading ...
Cellectar Reports Financial Results for the First Quarter 2021 and Provides a Corporate Update
May 10, 2021
Cellectar Strengthens Global IP Position with Phospholipid Drug Conjugate Composition of Matter Patent in Eurasia, Australia, and Mexico
April 27, 2021
New patent covers phospholipid-ether analogs combined with various small molecule chemotherapeutics and methods of use for PDCs™
28 Stocks Moving in Tuesday's Pre-Market Session
March 16, 2021
Gainers SunLink Health Systems, Inc. (NYSE: SSY) shares rose 82.4% to $3.52 in pre-market trading as the company reported $2 ...
Cellectar Granted Japanese Composition of Matter Patent for its Phospholipid-Ether Drug Conjugates
March 09, 2021
Covers phospholipid-ether analogs combined with various small molecule chemotherapeutics and methods of use for PDCs™
AavantiBio Adds Veteran Life Sciences Executive Douglas J. Swirsky as Chief Financial Officer and Treasurer
March 03, 2021
AavantiBio, a gene therapy company focused on transforming the lives of patients with rare genetic diseases, today announced the appointment of Douglas J. Swirsky as Chief Financial Officer and...
Cellectar Reports Financial Results for Year Ended December 31, 2020 and Provides a Corporate Update
March 02, 2021
12 Health Care Stocks Moving In Friday's After-Market Session
February 12, 2021
Gainers Bellicum Pharmaceuticals (NASDAQ:BLCM) stock moved upwards by 3.91% to $6.9 during Friday's after-market session. ...
Cellectar to Present at BIO CEO & Investor Digital Conference
February 10, 2021
3 Penny Stocks To Buy Under $2 & Analysts Have Targets Up To 367%
January 28, 2021
12 Health Care Stocks Moving In Thursday's After-Market Session
January 28, 2021
Gainers Novavax (NASDAQ:NVAX) shares increased by 25.93% to $168.77 during Thursday's after-market session. This security traded ...
Cellectar Receives Orphan Drug Designation from the European Commission for CLR 131 in Waldenstrom’s Macroglobulinemia
January 27, 2021
InvestorNewsBreaks – Cellectar Biosciences Inc. (NASDAQ: CLRB) Secures $45M in Underwritten Public Offering and Concurrent Private Placement
January 06, 2021
Top Penny Stocks Insiders Decided To Buy Before 2021
January 03, 2021
Thursday 12/31 Insider Buying Report: CLRB, FCBP
December 31, 2020
As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy -- they expect to make money. So let's look at two noteworthy recent insider buys.
From Market News Video
Cellectar Biosciences Announces Closing of $24.5 Million Underwritten Public Offering and $20.5 Million Concurrent Private Placement
December 28, 2020